

Title (en)

HLA TUMOR ANTIGEN PEPTIDES OF CLASS I AND II FOR TREATING MAMMARY/BREAST CARCINOMAS

Title (de)

HLA-TUMORANTIGENPEPTIDEN DER KLASSE I UND II ZUR BEHANDLUNG VON MAMMA-/BRUSTKARZINOMEN

Title (fr)

PEPTIDES D'ANTIGÈNES TUMORAUX HLA DE CLASSE I ET II POUR LE TRAITEMENT DES CARCINOMES MAMMAIRES ET/OU DU SEIN

Publication

EP 3976081 A1 20220406 (DE)

Application

EP 20734836 A 20200602

Priority

- DE 102019114735 A 20190602
- EP 2020065235 W 20200602

Abstract (en)

[origin: CA3140204A1] The invention relates to a pharmaceutical composition for use in the treatment or prophylaxis of mammary/breast carcinomas, in particular locally recurring or metastasizing mammary carcinomas in a patient or a patient group afflicted by a mammary/breast carcinoma or suspected to be afflicted by a mammary/breast carcinoma, comprising at least 4 to 8 HLA-A tumor antigen peptides corresponding to the MHC class I complexes and at least 2 tumor antigen peptides corresponding to the MHC class II complexes, wherein HLA tumor antigen peptides are tumor-exclusive or tumor-associated HLA antigen peptides and are directed against at least one MHC complex, including combinations thereof, a pharmaceutical composition, a kit (or parts thereof), a method for determining an HLA peptide of class I and/or II, a method for producing a formulation according to the invention, and the use of a formulation according to the invention for producing a pharmaceutical composition for treating malignancies, leukemia and neoplasias.

IPC 8 full level

A61K 38/04 (2006.01); **A61P 35/00** (2006.01)

CPC (source: CN EP US)

A61K 38/08 (2013.01 - CN EP); **A61K 38/10** (2013.01 - EP); **A61K 39/0011** (2013.01 - CN EP US); **A61K 39/39558** (2013.01 - CN); **A61P 15/00** (2018.01 - US); **A61P 15/14** (2018.01 - CN); **A61P 35/00** (2018.01 - CN EP US); **C07K 7/02** (2013.01 - US); **C07K 14/70539** (2013.01 - CN); **G01N 33/57415** (2013.01 - CN); **G01N 33/68** (2013.01 - CN); **A61K 2039/812** (2018.08 - CN)

C-Set (source: CN EP)

CN

1. **A61K 39/0011 + A61K 2300/00**
2. **A61K 39/39558 + A61K 2300/00**
3. **A61K 38/08 + A61K 2300/00**

EP

1. **A61K 38/08 + A61K 2300/00**
2. **A61K 38/10 + A61K 2300/00**
3. **A61K 39/0011 + A61K 2300/00**

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

DE 102019114735 A1 20201203; CA 3140204 A1 20201210; CN 114222583 A 20220322; EP 3976081 A1 20220406; US 2022313804 A1 20221006; WO 2020245126 A1 20201210

DOCDB simple family (application)

DE 102019114735 A 20190602; CA 3140204 A 20200602; CN 202080054783 A 20200602; EP 2020065235 W 20200602; EP 20734836 A 20200602; US 202017615595 A 20200602